Bioresorbable Urethral Implant with a unique composition

  • 70% CMC gel
  • 30% Polycaprolactone (PCL) microspheres

Minimally invasive procedure

Proven safety and efficacy

  • Safe product components with a long safety history in numerous CE marked and FDA approved bioresorbable medical devices
  • Soft bioresorbable (non-cross-linked) medical polymer: polycaprolactone, in a tailor made aqueous CMC gel carrier
  • Gel carrier components Generally Recognized As Safe (GRAS) by the USA FDA

Optimal biocompatibility

  • Sensitivity testing not required due to a non-animal, non-bacterial and non-human derived product
  • Due to microsphere size, spherical shape, smooth surface and chain scission (hydrolysis) as opposed to degradation

Bi-phasic hydrolytic bioresorption

  • Purely hydrolysis-based; non-enzymatic process
  • PCL microspheres remain in-situ, resulting in stable and sustained performance
  • Second-phase results in full bioresorption of small PCL chains (6-hydroxy caproic acid) via the normal citric acid cycle; reduction to CO2 and H2O)

Totally bioresorbable

  • Non-permanent microspheres
  • As shown by radio-labelled PCL studies
  • Reduced risk of long-term complications when compared to permanent implants

Urolon is a new class of urethral injectables. Its composition gives an immediate bulking effect primarily from the CMC gel carrier (70%) and sustained performance due to highly biocompatible PCL microspheres (30%)10-11. Combined, these unique advantages position Urolon as an ideal, first-choice and minimally invasive treatment option for women with mild to moderate SUI.